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Abstract
Introduction: There are limited data on factors associated with retention in Option B+. We sought to explore the
characteristics of women retained in Option B+ in Malawi, with a focus on the role of HIV disclosure, awareness of partner
HIV status, and knowledge around the importance of Option B+ for maternal–child health.
Methods: We performed a case-control study of HIV-infected women in Malawi initiated on antiretroviral therapy (ART)
under Option B+. Cases were enrolled if they met criteria for default from Option B+ (out of ART for >60 days), and controls
were enrolled in approximately 3:1 ratio if they were retained in care for at least 12 months. We surveyed socio-
demographic characteristics, HIV disclosure and awareness of partner HIV status, self-report about receiving pre-ART
education, and knowledge of Option B+. Univariate logistic regression was performed to determine factors associated
with retention. Multivariate logistic regression model was used to evaluate the relationship between HIV disclosure,
Option B+ knowledge, and retention after adjusting for age, schooling, and travel time to clinic.
Results: We enrolled 50 cases and 153 controls. Median age was 30 years (interquartile range (IQR) 25–34), and the majority
(82%) initiated ART during pregnancy at a median gestational age of 24 weeks (IQR 16–28). Ninety-one per cent of the cases
(39/43) who started ART during pregnancy defaulted by three months postpartum. HIV disclosure to the primary sex partner
was more common among women retained in care (100% versus 78%, p < 0.001). Odds of retention were significantly higher
among women with: age >25 years (odds ratio (OR) 2.44), completion of primary school (OR 3.06), awareness of partner HIV
status (OR 5.20), pre-ART education (OR 6.17), higher number of correct answers to Option B+ knowledge questions (OR
1.82), and support while taking ART (OR 3.65). Pre-ART education and knowledge were significantly correlated (r = 0.43,
p < 0.001). In multivariate analysis, awareness of partner HIV status (OR 4.07, 95% confidence interval (CI) 1.51–10.94,
p = 0.02) and Option B+ knowledge (OR 1.60, 95% CI 1.15–2.23, p = 0.004) remained associated with retention.
Conclusions: Interventions that address partner disclosure and strengthen pre-ART education around the benefits of ART for
maternal and child health should be evaluated to improve retention in Malawi’s Option B+ programme.
Keywords: HIV/AIDS; Option B+; Malawi; retention; prevention of mother-to-child transmission
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Introduction
Malawi was among the first countries in Africa to implement
the Option B+ prevention of mother-to-child transmission
(PMTCT) of HIV policy in July 2011 [1]. Under this policy, all
HIV-infected pregnant women and breastfeeding women are
started on antiretroviral therapy (ART) with a three-drug
regimen (efavirenz, tenofovir, and lamivudine) and continued
on treatment for life. Initiation is done regardless of CD4
count and clinical disease stage. The programme has
achieved high rates of coverage, with almost 80% of preg-
nant women on ART through decentralization of service
delivery utilizing antenatal clinics (ANCs) and maternity
clinics as sites for initiation [2]. Option B+ has reduced
rates of mother-to-child HIV transmission and resulted in
improvements in rates of antepartum ART initiation, infant
testing rates, and ART initiation in HIV-infected infants [2–5].
Despite these successes, there are high rates of loss to
follow-up from Option B+, particularly early after ART initia-
tion, with recent Ministry of Health quarterly report data
showing Option B+ retention of 76.8% at 12 months after
ART initiation. Retention further declines 24 and 36 months
after starting ART (70.8% and 69.7%, respectively), and
rates have not changed significantly as the Option B+ pro-
gramme has matured [6]. Factors associated with loss to
follow-up include receiving an HIV diagnosis on the same
day as ART initiation [7,8], younger age [7,9], cost and time
to travel to clinic [9], low knowledge around the benefits of
Option B+ for maternal and infant health [9], and non-
disclosure of HIV status [10,11]. The majority of studies
reporting these data are from women who missed appoint-
ments and/or defaulted and did not allow for comparison
to women retained in care.
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Early loss to follow-up from Option B+ is a threat to
achieving maximal benefits. Further work is needed to
help women remain in care and on ART during pregnancy,
breastfeeding, and future subsequent pregnancies. We
sought to explore characteristics of women retained in
Option B+ in central Malawi using a case-control design,
with a focus on identifying modifiable factors that could be
targets for programme interventions to improve retention
in care. We hypothesized that disclosure of HIV status to
the primary sex partner, awareness of partner HIV status,
and higher knowledge about the importance of Option B+
for maternal and child health would be associated with
retention in care after adjustment for the established fac-
tors of age, education, and distance from the ART clinic.
Methods
This study was performed under the umbrella of Expanding
QUality ImProvement (EQUIP)-Malawi, a President’s
Emergency Plan for AIDS Relief-United States Agency for
International Development-funded HIV care and treatment
programme. Women were recruited from 14 EQUIP-sup-
ported ART clinics in central Malawi between October
2014 and April 2015. Central Malawi contains 9 of the
country’s 27 districts and is largely rural with the exception
of the capital of Lilongwe. Women were recruited from
rural sites in the central region. Controls were defined as
HIV-infected women 18 years of age and older who started
ART under Option B+ and were retained in care ≥12 months.
Women in the control arm were approached during routine
ART clinic visits. Cases were defined as women who met
criteria for default from Option B+ based on the Malawi
national programme definition (out of ART for >60 days). Of
a total of 289 women who had defaulted from sites, 50
(17%) were located through standard tracing EQUIP-sup-
ported tracing protocols. At the time of tracing, women
were asked if they were interested in participating in the
study and were given the option to complete the survey in
a private place in their community or to complete the
survey in clinic at the time of their return appointment.
All 50 women approached for the study consented to
participate. Controls were enrolled in a 3:1 ratio. Written
informed consent was obtained from all women.
All women completed a 1-hour survey, which was admi-
nistered by a Malawian research assistant who asked ques-
tions in the local language (Chichewa). Survey domains
included socio-demographics including time for travel to
ART clinic, HIV diagnosis and treatment characteristics,
and disclosure status (disclosure to partner and awareness
of partner HIV status). Women were asked about the spe-
cific types of education they received prior to starting ART
(pre-ART education) and were asked to answer six multiple-
choice questions assessing knowledge about Option B+, as
follows: (1) Does ART help when you are pregnant to
protect the baby from HIV? (2) Does ART help when you
are breastfeeding to protect the baby from HIV? (3) How
long is ART needed for women who start treatment during
pregnancy or breastfeeding? (4) When should a baby born
to an HIV-positive woman get his/her first test for HIV? (5)
Does ART help to prevent HIV-negative partners from get-
ting infected through sex? (6) Is it safe to become pregnant
while taking ART? Finally, a list of barriers to retention in
care was compiled based on a literature review, and all
women were asked to select any barriers from the list
influencing their ability to remain in care. A similar process
was utilized to identify facilitators to ART.
Approval for research was granted by the Malawi College
of Medicine Research and Ethics Committee in Blantyre
(P.07/14/1603) and by the University of California, Los
Angeles Institutional Research Board (IRB #14–000287).
Statistical methods
Data were entered into a Microsoft Access database and
transferred into R Statistical Computing Environment (ver-
sion 3.3, Vienna, Austria) for analysis. Summary statistics
were performed on basic socio-demographic and HIV diag-
nosis and treatment characteristics. Univariate logistic
regression was performed to determine factors associated
with retention. A multiple logistic regression model was
used to evaluate HIV disclosure, awareness of partner HIV
status, and Option B+ knowledge with retention in care,
while adjusting for age, education, and travel time to clinic.
Factors selected for adjustment in the multivariate model
were based on published literature showing these variables
to be independently associated with retention among preg-
nant and postpartum women. The covariance matrix of
each multiple regression model was checked and there
were no correlations between variables greater than 0.4.
The variance inflation factor was also checked for each
model, and no variable had a factor greater than 1.5. A
second analysis was performed comparing barriers to
retention in care reported by cases and controls using chi-
square and Fisher’s exact tests. Summary statistics were
used to characterize facilitators of retention in Option B+.
Results
We enrolled 50 cases and 153 controls from October
2014 to April 2015. Median age was 30 years (interquar-
tile range (IQR) 25–34) and 115 (57%) were married/
monogamous, 30 (15%) married/polygamous, and 58
(29%) were not in a current partnership. The majority of
women (N = 175, 86%) were diagnosed with HIV during
their most recent pregnancy, and of these, 171 (98%)
were initiated on ART the same day they were tested
for HIV. Of the women known to be HIV infected prior to
the current pregnancy, 16 (57%) reported taking short-
course antiretrovirals for PMTCT at least once. The med-
ian gestational age at ART initiation was 24 weeks (IQR
16–28). Among defaulters (cases), 20 (40%) were lost to
follow-up prior to delivery, and 18 (36%) were lost
between delivery and three months postpartum. The
median weeks from ART initiation to default was 8.6
(IQR 0–26 and range 0–145). Among cases lost to fol-
low-up by three months postpartum, five either declined
to initiate ART or received a bottle of ART but never
started.
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All women retained in care who reported a primary sex
partner had disclosed their HIV status to this individual,
compared to 78% of women who defaulted (p < 0.001).
Odds of retention were significantly higher among women
with age >25 years (odds ratio (OR) 2.44), completion of
primary school (OR 3.06), awareness of partner HIV status
(OR 5.20), those who received pre-ART education (OR 6.17),
those with a higher number of correct answers to Option B
+ knowledge questions (OR 1.82), and individuals with one
or more methods of support while taking ART (OR 3.65).
Travel time of >3 hours to clinic and later gestational age at
ART initiation were associated with significantly reduced
odds of retention (OR 0.13 and 0.95, respectively) (Table 1).
In the multivariate model, pre-ART education and knowl-
edge were significantly correlated (r = 0.43, p < 0.001), and
therefore, only knowledge was included in the analysis.
Additionally, disclosure to partner was excluded from multi-
variate analysis because 100% of controls disclosed.
Awareness of partner HIV status (OR 4.07, 95% confidence
interval (CI) 1.51–10.94, p = 0.02) and Option B+ knowledge
(OR 1.60, 95% CI 1.15–2.23, p = 0.004) remained associated
with retention (Table 2).
In the comparison of barriers to retention among cases
and controls, lack of time to attend clinic, difficulty with
money for transport to clinic, ART side effects, and poor
treatment by clinic staff were more commonly reported by
cases (Figure 1). There were no significant differences for
other barriers, including desire to see a traditional healer
or take non-ARV treatments, remembering to take ART
every day, fear of individuals finding out about HIV status,
lack of partner support, and lack of privacy at health
centres.
All women were asked about types of support (facilita-
tors) that would help them to engage in ART as part of the
Option B+ programme, and 200 (98.5%) responded affirma-
tively to at least one facilitator. For the combined cohort of
cases and controls, women most frequently requested sup-
port for growing food (84.2%), support from primary part-
ner (79.3%), more education about HIV and ART (78.2%),
having been HIV tested with the primary partner (75.7%),
and support groups either in the community (73.4%) or in
clinic (71.9%). Women retained in care were more likely to
respond affirmatively to assistance with disclosure despite
the fact that all had disclosed to their primary partner. They
were also more likely to respond affirmatively to the facil-
itators of support from primary partner, assistance for dis-
closure to those outside of primary partnership (family,
friends, and community), and more privacy at the health
facility (Table 3).
Discussion
Data from this study support the published literature
demonstrating that younger age [7,9], lower level of educa-
tion [9], and longer distance from clinic [9] are important
barriers to retention in Option B+. Our data add to the
existing literature by showing that when controlling for the
aforementioned known factors, disclosure to the primary
partner and awareness of partner HIV status remains
strongly associated with retention. In a cross-sectional
study of Option B+ in Ethiopia, disclosure was found to be
associated with good adherence to ART [11], and a study
from Papua New Guinea found that having a partner tested
was associated with retention and infant HIV-free survival
[12]. A small qualitative study from Zimbabwe showed
benefit of a community-based mentor mother programme
on retention, but noted non-disclosure as an important
barrier that prevented participation in this type of support
programme [13]. Likewise, two qualitative studies of Option
B+ women in Malawi found non-disclosure as a reason for
stopping ART [14,15]. In both of these studies, starting ART
on the same day of HIV diagnosis was a barrier to retention
because it resulted in lack of time to accept the diagnosis
and did not allow women to disclose and gain partner
support for treatment. While our study did not show an
association between same-day ART initiation and lower
retention, several other studies have reported this finding
[7,8,16].
Interventions addressing disclosure could result in signif-
icant improvements in Option B+ retention and ideally
should include strategies to engage male partners and
foster supportive partnerships in order to have sustained
benefit. The importance of addressing gender inequality as
a means to end vertical transmission of HIV has been raised
with a solution of “gender transformative PMTCT pro-
grammes” [17]; however, translating policy into practice
remains a challenge. For women who feel unable to start
ART on the same day of HIV diagnosis due to issues with
disclosure and/or securing partner support, allowing a short
delay in initiation during which they can be linked to sup-
port (assisted disclosure) may facilitate uptake and reten-
tion. This should be done in the setting of established
tracing protocols, in the event they do not return for
care. Treatment delays must be weighed against benefits
of treatment during pregnancy, particularly for those diag-
nosed with HIV late in pregnancy [18].
In addition to disclosure, lack of knowledge about HIV/
ART has also been raised as a barrier to retention in other
small studies of Option B+ women. In a study from Malawi,
10% of women reported limited understanding of ART as a
reason for stopping treatment [9]. Women participating in
two qualitative studies in Malawi also reported insufficient
understanding of the importance of ART for life and felt
they had inadequate counselling about Option B+ prior to
initiation [14,15]. It is possible that the move to “Test and
Start” in Malawi, in which all HIV-infected individuals will
be offered ART, will reduce scepticism around the need for
lifelong ART by removing qualifications for ART among
subpopulations and through education campaigns targeting
the benefits of ART for all HIV-infected individuals.
However, pregnant and postpartum women remain
uniquely vulnerable to loss to follow-up, and targeted edu-
cation for this group is important. Women may need infor-
mation and reassurance about the safety of ART during
pregnancy and breastfeeding, as well as the safety of con-
ceiving on ART. Additionally, understanding the benefits of
ART for prevention of transmission to HIV-uninfected part-
ners could be a powerful motivator for women to remain in
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Table 1. Univariate regression for the outcome of retention in Option B+, n = 203a.
Variablea
Casesc
(n = 50)
Controlsc
(n = 153)
Odds ratio
(95% confidence
interval) p-Valueb
Age
18–25 21 (43) 36 (24) 1.00 (Reference) 0.01
>25 28 (57) 117 (76) 2.44 (1.24–4.81)
Education
Less than primary school 44 (88) 108 (71) 1.00 (Reference) 0.009
Primary school and beyond 6 (12) 45 (29) 3.06 (1.22–7.69)
Duration to travel to ART clinic
≤1 hour 12 (24) 82 (54) 1.00 (Reference) <0.001
>1 hour up to 3 hours 27 (54) 61 (40) 0.33 (0.15–0.70)
>3 hours 11 (22) 10 (6) 0.13 (0.05–0.37)
Diagnosed with HIV during the most recent pregnancy?
No 4 (8) 24 (16) 1.00 (Reference) 0.15
Yes 46 (92) 129 (84) 0.47 (0.15–1.43)
ART initiation on the same day as HIV diagnosis?
No 2 (4) 13 (9) 1.00 (Reference) 0.26
Yes 44 (96) 127 (91) 0.44 (0.10–2.03)
Status at ART initiation
Pregnancy 43 (86) 123 (80) 1.00 (Reference) 0.36
Breastfeeding 7 (14) 30 (20) 1.50 (0.61–3.66)
Gestational age in weeks at ART start among those pregnant, median (IQR) 26 (16–32) 24 (16–28) 0.95 (0.91–0.99) 0.01
Participant aware of partner’s HIV status?
No 17 (47) 16 (15) 1.00 (Reference) 0.001
Yes 19 (53) 93 (85) 5.20 (2.24–12.07)
Not applicable 14(28) 44 (28.8) 3.34 (1.34–8.30)
Received pre-ART educationd
No 28 (56) 26 (17) 1.00 (Reference) <0.001
Yes 22 (44) 126 (83) 6.17 (3.06–12.43)
Correctly answered Option B+ knowledge questions (out of six questions),
median (IQR)
Number of knowledge questions answered correctly 4 (3–4) 4 (4–5) 1.82 (1.35–2.45) <0.001
0–2 11 (22) 12 (8) 1.00 (Reference) 0.006
3–4 30 (60) 86 (56) 2.63 (1.05–6.58)
5–6 9 (18) 55 (36) 5.60 (1.90–16.49)
No 28 (56) 26 (17) 1.00 (Reference) <0.001
Yes 22 (44) 126 (83) 6.17 (3.06–12.43)
Received support while taking ARTe
No 6 (13) 6 (4) 1.00 (Reference) 0.04
Yes 40 (87) 146 (96) 3.65 (1.12–11.93)
aAll variables reported as N (%) unless otherwise noted.
bCalculated with chi-square test.
cCases defined by Malawi National definition of default = out of ART for more than 60 days; controls were required to be in care for at least
12 months.
dBased on self-report of learning about five different Option B+ topics prior to starting ART.
eSupport was defined by use of support groups at the clinic or in the community, reminders for appointments, peer mentoring, or other
counselling.
ART: antiretroviral therapy; IQR: interquartile range.
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care. Counselling and education interventions should be
inexpensive, scalable, and cost-effective.
In our survey of barriers to retention in Option B+, we
found that time to travel to clinic, costs of traveling to
clinic, and poor treatment by clinic staff were more com-
monly reported by women who were lost to follow-up.
Differentiated models of care focused on Option B+
women may be one important strategy for addressing
these barriers. A study from Malawi showed that “models
of care” in which women are treated are associated with
retention. Investigators found highest retention when ART
initiation and maintenance were both done within ART
clinics rather than at ANC [19]. A second randomized
study from Kenya evaluated integration of ANC and
PMTCT services and found that benefits were seen for
uptake of ART but not for retention [20]. Strategies that
reduce the burden of time and cost for travel to clinic
include community ART groups or treatment adherence
groups where ART is distributed locally in a supportive
setting with other HIV-infected pregnant and postpartum
women on ART. These types of models may be particularly
facilitative for those experiencing poor treatment in clinical
settings, as was reported by women in our population and
in other studies of PMTCT [21,22].
Table 2. Multivariate regression for the outcome of retention in Option B+, n = 203.
Variablea
Cases
N = 50
Controls
N = 153
Multivariate
odds ratio (95%
confidence interval) p-Value
Age
18–25 21 (43) 36 (24) 1.00 (Reference) 0.015
>25 28 (57) 117 (76) 2.71 (1.21–6.06)
Education
Less than primary school 44 (88) 108 (71) 1.00 (Reference) 0.109
Primary school and beyond 6 (12) 45 (29) 2.24 (0.80–6.26)
Duration of travel to antiretroviral therapy clinic
≤1 hour 12 (24) 82 (54) 1.00 (Reference) 0.005
>1–3 hours 27 (54) 61 (40) 0.39 (0.17–0.90)
≥3 hours 11 (22) 10 (6) 0.16 (0.05–0.53)
Participant aware of partner’s HIV status?
No 17 (47) 16 (15) 1.00 (Reference) 0.016
Yes 19 (53) 93 (85) 4.07 (1.51–10.94)
No partner 14(28) 44 (29) 3.70 (1.25–10.96)
Number of knowledge questions answered correctly 4 (3–4)b 4 (4–5)b 1.60 (1.15–2.23) 0.004
aAll variables reported as N (%) unless otherwise noted.
bData presented as median (interquartile range).
Figure 1. Common barriers to retention in Option B+ reported by cases versus controls (n = 203)*.
*p-Values calculated using Fisher’s exact test.
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Side effects of ART emerged as another important barrier
for women lost to follow-up from Option B+. Two other
small studies from Malawi have reported this same finding
for Option B+ women. In the first study, side effects were
reported by 10% of women who stopped ART [9], and in
the second study, half of women (13/26) who stopped ART
reported stopping due to side effects. In this latter cohort,
almost all women reported at least one side effect, largely
within the first few weeks of initiation [14]. There are
several studies of integrase inhibitor-based ART in develop-
ment, including one in pregnant and postpartum women
[23]. These regimens may result in improved tolerability
and are likely to be available in generic, low-cost formula-
tions. Pending results of these clinical trials and the avail-
ability of newer regimens, counselling around side effects
of ART, and support for women experiencing challenges
with tolerability, including options to switch regimens,
may help to improve retention in Option B+.
Women identified a number of types of support that
would improve their ability to start and remain on ART.
Women retained in care were more likely to identify the
need for support for disclosure despite the fact that they all
reported disclosure to their primary partner. Perhaps, hav-
ing performed disclosure provided insight into the need for
better preparation for this experience. Many of the factors
identified by women in our study have been identified in
other cross-sectional studies of PMTCT in the pre-Option-B+
era or in the setting of Option B+, including nutrition sup-
port for improved food security [14,21,24], support groups
[21,25], and community health worker programmes
[14,26]. Women reported HIV testing with their partner as
a potentially helpful facilitator. In a recent study in Malawi,
pregnant women were randomized to receive an invitation
for partner HIV co-testing in ANC versus receiving an invita-
tion for co-testing with tracing if the partner did not return
for testing [27]. Invitation with partner tracing was found to
increase the proportion of couples HIV tested together
without causing harm. The impact on retention in care
was not assessed and should be investigated in further
studies.
There have been few interventional studies on strategies
to improve retention. A South African study of mobile-
phone-based case management in Option B+ women
showed that phone communication was acceptable and
improved rates of HIV infant testing but did not have an
impact on 12-month retention, although efficacy analysis
was limited by small sample size [28]. Thirty-nine per cent
of women in our study identified cell phone reminders as a
type of support that might help them take ART and return
for clinic appointments. However, results from this South
African study may not be easily generalized to Malawi due
to differences in availability of mobile phones and mobile
coverage, particularly in remote rural areas. The Promoting
Retention among Infants and Mothers Effectively (PRIME)
study is a cluster randomized intervention being performed
in Malawi and will evaluate the effectiveness of text mes-
sage reminders for mother–infant pairs who miss appoint-
ments, with the primary outcome of 12-month postpartum
retention [29]. A second large randomized study in Malawi,
The PMTCT Uptake and Retention (PURE) study, is a three-
Table 3. Summary of facilitators to retention in Option B+ reported by cases and controls (n = 200).
Facilitatorsa
(What types of support would have helped you or would
make it easier for you to take ART?)
Number of women in control
group responding yes (%)
Number of women in case
group responding yes (%) p-Valuesb
Support for growing food 133 (86.9) 38 (76.0) 0.08
Support from primary partner 128 (83.7) 33 (66.0) 0.01
More education about HIV, ART, and how to stay healthy 122 (80.3) 36 (72.0) 0.23
Having been HIV tested with primary partner 117 (77.0) 36 (72.0) 0.48
Support groups in the community 117 (77.0) 32 (64.0) 0.09
Support groups in clinic 114 (74.5) 32 (64.0) 0.16
Assistance to disclose to primary partner 104 (68.0) 24 (48.0) 0.01
Assistance to disclose to others (family, friends, and
community members)
104 (68.0) 23 (46.0) 0.01
Better privacy at the health centre 104 (68.0) 23 (46.0) 0.01
Having an ART clinic closer to your home 91 (59.5) 29 (58.0) 0.85
Decrease in the number of times needed to visit the
health centre for ART refills
76 (49.7) 23 (46.9) 0.74
Help remembering to take ART or come to clinic from a
person
72 (47.1) 18 (36.0) 0.17
Help remembering to take ART or come to clinic with a
phone call or text message
64 (41.8) 16 (32.0) 0.21
aWomen could respond yes to more than one type of support.
bCalculated by chi-square or Fisher’s exact tests.
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arm cluster randomized trial to evaluate clinic- or commu-
nity-based peer support with retention as an outcome for
women, infants, and male partners [30]. These studies will
provide much needed rigorous data on strategies to
improve Option B+ retention.
Limitations
Our study was limited by the small number of women who
defaulted (cases), which limited the number of factors
included in the multivariate model. We initially planned to
enrol cases in a 1:1 fashion but had difficulty tracing
women who had been lost to follow-up. Additionally,
women who defaulted and were successfully traced may
be different from women who cannot be traced. We per-
formed the study to gain preliminary data for larger inter-
ventions and, therefore, did not correct for multiple
statistical tests. Our survey was administered by a female
Malawian trained in quantitative and qualitative research
data collection; however, women in Malawi can be reluc-
tant to report their experiences in a research setting. It is
possible that women did not reveal all relevant barriers
during the survey. Our sample included women from cen-
tral Malawi and, therefore, may not be generalizable to all
regions in Malawi or other settings in Sub-Saharan Africa.
Conclusions
Interventions that address partner disclosure and gender
dynamics and those that strengthen pre-ART education
around the benefits of ART for maternal and child health
should be evaluated as strategies to improve retention in
Malawi’s Option B+ programme. Differentiated models of
care for pregnant and postpartum women hold promise as
strategies to help overcome additional barriers to retention,
such as time and cost of travel to ART clinics. Consideration
should be given to whether ART side effects are playing a
role in adherence and retention. The era of Test and Start
may result in improved identification of HIV-infected men
and raise opportunities for partner testing and family-based
support for adherence and retention.
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